NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Secondary HyperoxaluriaNephrolithiasisHyperoxaluriaKidney StonesDietary Hyperoxaluria

Interventions

DRUG

ALLN-177

ALLN-177 7,500 units (5 capsules) PO TID with meals

DRUG

Placebo

Placebo 5 capsules PO TID with meals

Trial Locations (22)

12601

Premier Medical Group of the Hudson Valley, Poughkeepsie

23462

Urology of Virginia, Virginia Beach

27612

Associated Urologists of North Carolina, Raleigh

28401

Coastal Urology, Wilmington

29572

Carolina Urologic Research Center, Myrtle Beach

32114

Atlantic Urological Associates, Daytona Beach

33060

Clinical Research Center of Florida, Pompano Beach

33180

South Florida Medical Research, LLC, Aventura

44130

Clinical Research Solutions, LLC, Middleburg Heights

45212

Tristate Urologic Services PSC INC. DBA The Urology group, Cincinnati, OH

46202

IU Health Physicians Urology, Indianapolis

71106

Regional Urology, LLC, Shreveport

72212

Applied Research Center of Arkansas, Inc., Little Rock

75231

Urology Clinics of North Texas PLLC, Dallas

83642

Idaho Urological Institute, Meridian

85054

Mayo Clinica Arizona, Pheonix

85741

Urological Associates of Southern Arizona, PC, Tuscon

98043

Integrity Medical Research, Mountlake Terrace

555905

Mayo Clinic Department of Medicine Clinical Trials Unit, Rochester

02114

Massachusetts General Hospital, Boston

08043

Delaware Valley Urology, LLC, Voorhees Township

02886

Omega Medical Research, Warwick